Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them
Cervical cancer remains a leading cause of cancer death in women, and outcomes in recurrent or metastatic disease remain poor despite chemoradiation and bevacizumab. The HPV-driven biology that defines the disease—viral E6/E7 oncoproteins, an inflamed …